Application and Effect
Desvenlafaxine Succinate increases the treatment of serotonin and norepinephrine by inhibiting reuptake mechanisms. More importantly, norvenlafaxine succinate is not a hormonal drug and will become the preferred medication for patients with menstrual syndrome. Desvenlafaxine is also being developed for the treatment of moderate to severe vasomotor symptoms associated with menopause (i.e., hot flashes and night sweats) and is also in phase III clinical trials to study it’s effectiveness in treating fibromyalgia and neuropathic pain.Product Sample
Product Packing:
Additional Information:
| Composition | C20H31NO6 |
| Assay | 99% |
| Appearance | White powder |
| CAS No. | 386750-22-7 |
| Packing | 25KG |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |